Prescription drug bulk purchasing agreements can save patients money but could hinder their health outcomes as a result of reduced access to favourable medicines.
The global biosimilar drug market for 2013 will see a 20% growth on last year’s figures to a whopping $2.44 billion, and a new survey indicates that this trend will continue to flourish for the next decade.
Kevin Dolgin speaks to eyeforpharma about pharma's ongoing "crisis" and how improving patient adherence could provide a much needed injection of capital into your bottom line...
An innovative form of 3D technology could eliminate atrial fibrillation caused by the electronic signals in the heart, a major step forward in the treatment of this condition.
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type launches to continue to be the norm within the pharmaceutical industry.
Forceful efforts to thwart generic drug competition in France have landed multinational pharma firm Sanofi in deep water with the country’s Competition Authority, which has just issued a €40.6m ($52.7m) fine for a smear campaign targeted at the company’s rivals several years ago.
In the largest US drug safety settlement to date with a generic drug manufacturer, agreement was reached with Ranxbury USA Inc. for a total payment of US$500 million as well as guilty pleas to multiple felony charges.
Matthew Bonam, Pharmaceutical Projects Director at AstraZeneca and Tim Davis, chief executive of Exco InTouch discuss their collaboration and the virtues of mHealth in combatting chronic obstructive pulmonary disease.
With digital adoption no longer an option, but a must, and the growing influence of customers within the pharma industry, your company needs a comprehensive approach that addresses both digital and customer in a complimentary and comprehensive way…
"Is pharma slow to adopt digital?" If you're still asking yourself this question, or some iteration of it, then I think both you and I already know the answer...
Petteri Jarkka, Customer Engagement Manager at Janssen Nordic, talks to eyeforpharma about how the company is responding to recent calls for a ‘beyond the pill’ approach, and how they’re working with stakeholders to ‘co-create’ services improve health outcomes.
EU citizens are unable to afford life-saving medication due to ongoing cuts and austerity measures, according to a Member of the European Parliament.
Pharma firms are looking to collaborate with the right delivery device partners as a number of rapidly changing factors across the pharmaceutical landscape converge and create the demand for alternate drug delivery technologies.
New findings suggest that if recent steps taken by the CIS countries are seen through to completion, it will revolutionize the pharma landscape, and open up access to medicines in these countries.
Ben Steele talks with Eduardo Tchouhadjian, CEO of E. Tchouhadjian & Associates, about how companies in Latin America are responding to the rise of the ‘smart patient’ and how to use “360-degree marketing” to combat the issue of prescription switching in these fast-growing markets.
Lucy Brake speaks to Mike Rea, CEO of IDEA Pharma, about how he believes real world evidence impacts current development and trials processes, and the ways in which pharma can take best take advantage of all this offers.